Skip to main content

Table 3 Descriptive statistics of confirmed COVID-19 cases

From: Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

Parameter ((Mean ± SD/ Q1,Median,Q3) or (#\%)) Treatment strategy
Confirmed cases (9) Home-based care (4) Hospital admission (5)
Age 49.22 ± 7.94 [41–64] 51.25 ± 9.63 [41–64] 47.6 ± 7.02 [42–59]
P-value a: 0.530 b
 Sex Male 4 (44.4%) 1 (25%) 3 (60%)
Female 5 (55.6%) 3 (75%) 2 (40%)
Disease duration 9.33 ± 5.31 [4–18] 10.00 ± 6.32 [4–18] 8.80 ± 5.06 [4–15]
P-value a: 0.760 b
 Walking disability 1.78 ± 1.30 [1–5] 2.00 ± 2.00 1.6 ± 0.54
P-value a: 0.730 c
 Number of Rituximab injections so far Once 0 (0%) 0 (0%) 0 (0%)
Twice 3 (33.3%) 2 (50%) 1 (20%)
Thrice 0 (0%) 0 (0%) 0 (0%)
>  4 doses 6 (66.6%) 2 (50%) 4 (80%)
 Extended Interval Dosing Positive 2 (22.2%) 2 (50%) 1 (20%)
Negative 7 (77.7%) 2 (50%) 4 (80%)
 Comorbidity Positive 0 (0%) 0 (0%) 0 (0%)
Negative 9 (100%) 4 (100%) 5 (100%)
 Recent relapse Positive 0 (0%) 0 (0%) 0 (0%)
Negative 9 (100%) 4 (100%) 5 (100%)
 Corticosteroids consumption positive 1 (11.1%) 1 (25%) 0 (0%)
Negative 8 (88.8%) 3 (75%) 5 (100%)
 self-isolation Positive 6 (66.6%) 3 (75%) 3 (60%)
Negative 3 (33.3%) 1 (25%) 2 (40%)
 COVID-19 contact Positive 4 (44.4%) 1 (25%) 4 (80%)
Negative 5 (55.5%) 3 (75%) 1 (20%)
 Final outcome Cured/Discharged 7 (77.7%) 4 (100%) 3 (60%)
Death 2 (22.2%) 0 (0%) 2 (40%)
Incidence Rate Mild to Moderate Condition Serious Condition Case Fatality Rate
3.4% 44.4% 11% 22.2%
  1. a: Comparison between treatment strategies which were finally required for patient’s management; b: Student T-test; c: Mann-Whitney U test